E Fund Management Co. Ltd. Has $1.85 Million Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

E Fund Management Co. Ltd. raised its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 6.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,644 shares of the company’s stock after acquiring an additional 4,076 shares during the period. E Fund Management Co. Ltd. owned about 0.12% of Janux Therapeutics worth $1,853,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LPL Financial LLC acquired a new position in shares of Janux Therapeutics during the fourth quarter worth about $439,000. Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 714,956 shares of the company’s stock worth $38,288,000 after buying an additional 52,362 shares during the period. Wells Fargo & Company MN boosted its position in shares of Janux Therapeutics by 52.9% during the fourth quarter. Wells Fargo & Company MN now owns 13,251 shares of the company’s stock worth $709,000 after buying an additional 4,585 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares during the period. Finally, Cerity Partners LLC acquired a new position in shares of Janux Therapeutics during the fourth quarter worth about $239,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Performance

JANX opened at $24.96 on Thursday. Janux Therapeutics, Inc. has a 52-week low of $21.97 and a 52-week high of $71.71. The firm has a market capitalization of $1.50 billion, a PE ratio of -13.87 and a beta of 2.86. The business’s 50-day simple moving average is $24.62 and its 200 day simple moving average is $28.66.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Raymond James Financial assumed coverage on Janux Therapeutics in a research report on Friday, July 11th. They set an “outperform” rating and a $65.00 price objective for the company. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $91.89.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.